Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.